NCT05654870: An ongoing trial by Neurocrine Biosciences
This trial is completed, but has been granted a delay in reporting its results.
It must report results 10 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05654870 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 5, 2023 |
| Completion date | Nov. 8, 2023 |
| Required reporting date | Nov. 8, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |